Recent research focusing on Delta-like protein 3 (DLL3) and seizure-related 6 homolog (SEZ6) expression reveals significant associations in neuroendocrine neoplasms (NENs), especially high-grade tumors, such as lung neuroendocrine carcinomas and Merkel cell carcinomas. A study involving 213 tumor specimens categorized by the 2022 WHO guidelines assessed DLL3 and SEZ6 expression through immunohistochemical techniques. The findings indicate that DLL3 positivity is predominantly observed in high-grade NENs, while SEZ6 has broader expression across various types, including medullary thyroid carcinomas and duodenal NETs.

Source: Endocrine Pathology